Skip to main content

Table 3 HR (95% CI) of stratified analysis across tertiles of serum choline levels

From: Serum choline is associated with hepatocellular carcinoma survival: a prospective cohort study

 Liver cancer-specific survivalOverall survival 
T1T2T3P-trendP-interactionT1T2T3P-trendP-interaction
Sexa, b    0.511    0.781
 Men1.000.77 (0.56–1.07)0.66 (0.48–0.92)0.013 1.000.80 (0.58–1.10)0.71 (0.52–0.98)0.037 
 Women1.001.21 (0.41–3.52)1.59 (0.57–4.44)0.360 1.001.15 (0.42–3.14)1.33 (0.50–3.54)0.567 
Agea, b, years    0.838    0.801
  < 601.001.03 (0.72–1.48)0.69 (0.48–0.99)0.031 1.001.07 (0.75–1.52)0.74 (0.52–1.06)0.070 
  ≥ 601.000.80 (0.42–1.51)0.63 (0.34–1.17)0.142 1.000.83 (0.45–1.53)0.65 (0.36–1.18)0.155 
BMIa, b, kg/m2    0.357    0.436
  < 25.01.000.90 (0.64–1.27)0.74 (0.53–1.04)0.079 1.000.88 (0.62–1.23)0.77 (0.55–1.07)0.117 
  ≥ 25.01.001.15 (0.54–2.44)0.47 (0.20–1.10)0.118 1.001.03 (0.50–2.12)0.61 (0.28–1.32)0.185 
Smoking statusa, b    0.820    0.756
 Smoker1.000.58 (0.39–0.85)0.57 (0.39–0.83)0.010 1.000.61 (0.42–0.89)0.61 (0.42–0.88)0.013 
 Non-smoker1.001.17 (0.69–1.98)0.85 (0.50–1.42)0.481 1.001.19 (0.71–2.01)0.91 (0.55–1.51)0.669 
Drinking statusa, b    0.388    0.399
 Drinker1.000.67 (0.41–1.07)0.78 (0.50–1.22)0.342 1.000.71 (0.44–1.13)0.75 (0.48–1.16)0.237 
 Non-Drinker1.001.23 (0.82–1.86)0.72 (0.47–1.12)0.077 1.001.16 (0.77–1.74)0.74 (0.49–1.13)0.135 
AFP levela, b, ng/mL    0.160    0.566
  ≥ 4001.000.85 (0.56–1.30)0.80 (0.52–1.22)0.300 1.000.86 (0.57–1.29)0.83 (0.56–1.25)0.385 
  < 4001.000.87 (0.55–1.37)0.68 (0.43–1.06)0.085 1.000.91 (0.58–1.42)0.73 (0.48–1.13)0.155 
CRP levela, b, mg/L    0.010    0.005
  ≥ 3.01.000.91 (0.64–1.29)0.60 (0.41–0.88)0.008 1.000.92 (0.65–1.29)0.63 (0.44–0.91)0.013 
  < 3.01.001.34 (0.70–2.56)1.37 (0.74–2.51)0.353 1.001.34 (0.71–2.54)1.47 (0.81–2.67)0.224 
Serum folate levela, b    0.782    0.946
 High1.001.07 (0.67–1.70)0.79 (0.50–1.26)0.279 1.001.17 (0.74–1.84)0.91 (0.58–1.43)0.583 
 Low1.000.96 (0.62–1.47)0.77 (0.50–1.17)0.207 1.000.94 (0.62–1.42)0.76 (0.50–1.14)0.170 
Liver damage levela, b    0.520    0.602
 11.001.39 (0.34–5.74)1.54 (0.40–6.00)0.547 1.001.85 (0.52–6.62)1.16 (0.34–3.97)0.935 
 21.001.06 (0.63–1.78)0.58 (0.33–1.01)0.045 1.001.06 (0.63–1.78)0.65 (0.38–1.13)0.114 
  ≥ 31.000.82 (0.55–1.22)0.72 (0.48–1.08)0.115 1.000.86 (0.58–1.26)0.78 (0.53–1.14)0.206 
Presence of fatty livera, b    0.385    0.842
 Yes1.001.08 (0.38–3.07)0.94 (0.32–2.78)0.902 1.001.05 (0.40–2.76)1.17 (0.45–3.03)0.741 
 No1.000.94 (0.68–1.30)0.69 (0.50–0.97)0.026 1.000.96 (0.70–1.32)0.72 (0.52–0.99)0.035 
Presence of cirrhosisa, b    0.518    0.170
 Yes1.000.93 (0.60–1.43)0.83 (0.54–1.27)0.380 1.000.93 (0.61–1.42)0.90 (0.60–1.35)0.602 
 No1.000.98 (0.63–1.52)0.63 (0.39–1.00)0.048 1.001.01 (0.66–1.56)0.62 (0.39–0.98)0.039 
BCLC stagea, b    0.774    0.502
 0/A1.000.80 (0.34–1.90)0.72 (0.32–1.62)0.440 1.000.91 (0.40–2.11)0.78 (0.35–1.73)0.515 
 B/C1.000.89 (0.64–1.23)0.64 (0.46–0.90)0.008 1.000.88 (0.63–1.21)0.67 (0.48–0.93)0.014 
Treatmenta, b    0.333    0.480
 Liver resection1.001.29 (0.69–2.41)0.81 (0.42–1.56)0.536 1.001.16 (0.63–2.14)0.87 (0.46–1.62)0.664 
 Intervention1.000.75 (0.51–1.10)0.60 (0.41–0.86)0.006 1.000.80 (0.55–1.17)0.64 (0.45–0.92)0.015 
 Others1.001.26 (0.52–3.07)0.95 (0.37–2.42)0.908 1.001.21 (0.49–2.94)1.00 (0.40–2.50)0.985 
  1. a Covariates adjusted for age, sex, BMI, education level, smoking status, baseline liver damage level, BCLC stage, treatment, AFP level and CRP level
  2. b Stratified factors were not included in the corresponding models